10 citations
,
October 2015 in “Journal of the International Association of Providers of AIDS Care” A woman with HIV had a severe skin condition that improved with antiretroviral therapy.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
29 citations
,
March 2016 in “Dermatologic therapy” Platelet-rich plasma may successfully treat lichen planopillaris, as shown by one patient's symptom regression.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
July 2026 in “Journal of Medicinal Chemistry” A new drug strategy improves hair loss treatment with better results and safety.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
July 2026 in “Journal of the American Academy of Dermatology” Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.
8 citations
,
December 2018 in “Journal of Dermatological Treatment” The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
December 2015 in “Vascular Pharmacology” Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
6 citations
,
June 2011 in “British Journal of Dermatology” People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
1 citations
,
May 2025 in “The Journal of Rheumatology” Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
August 2016 in “Anaplastology” The new controlled release PRP therapy shows promise for hair growth in women.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
3 citations
,
November 2023 in “Journal of Investigative Dermatology” Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
July 2025 in “Journal of Clinical Medicine” Platelet-rich concentrates can be an alternative treatment for oral lichen planus, especially when steroids don't work.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
8 citations
,
December 2023 in “International Journal of Molecular Sciences” Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.
June 2025 in “Neurology India” Anti-SRP myopathy can be linked to systemic lupus erythematosus and may improve with specific treatment.
3 citations
,
November 2016 in “Journal of Pakistan Association of Dermatology” PRP is a safe and effective treatment for limited alopecia areata.
October 2023 in “European journal of dermatology/EJD. European journal of dermatology” Injectable platelet-rich fibrin can safely and effectively treat melasma.